• Clemens Warnke, Olaf Stüve, and Bernd C Kieseier.
• Department of Neurology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
• Clin Neurol Neurosurg. 2013 Dec 1;115 Suppl 1:S90-4.

AbstractTeriflunomide is a new active drug which has recently been approved as a first-line treatment of relapsing forms of MS in the US, Australia, Argentina, and the European Union. It is characterized by a once-daily oral application and a well-established long-term safety profile. The main therapeutic effect is considered to be mediated via the inhibition of the de novo synthesis of pyrimidine in proliferating immune cells. Two phase III clinical trials (TEMSO, TOWER) tested teriflunomide in patients with relapsing forms of MS: efficacy was shown, with positive effects on relapse rates and disease progression for 14 mg/day. Overall, the safety profile in these studies was favorable. In patients treated with teriflunomide, the regular monitoring of blood cell counts and liver enzymes is required. Teriflunomide must not be used during pregnancy. In this article, we review recent phase II and phase III clinical trial data, and discuss the potential of teriflunomide for the treatment of relapsing forms of MS.Copyright © 2013. Published by Elsevier B.V.

22 keywords...

hide…